Frost & Sullivan Independent Equity Research

Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged


Company: Cellect Biotechnology Ltd.        

Sector: Biotechnology

Report type: Annual 2017, Q1-2018 and 12 mos. Since Initiation Updates

Published on: 30 May, 2018

Cellect research articles: